Biomarkers on melanoma patient T cells associated with ipilimumab treatment. - Wikidata - wikimedia - TriplyDB

Biomarkers on melanoma patient T cells associated with ipilimumab treatment.

Biomarkers on melanoma patient T cells associated with ipilimumab treatment.

http://www.wikidata.org/entity/Q36480617

about

Novel technologies and emerging biomarkers for personalized cancer immunotherapy Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?Immune Checkpoint Blockade in Cancer Therapy Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients Monitoring the immune competence of cancer patients to predict outcome.Therapeutic use of anti-CTLA-4 antibodies.Developing biomarker-specific end points in lung cancer clinical trials.Immune checkpoint combinations from mouse to man.Immunological landscape and immunotherapy of hepatocellular carcinoma.Immunomodulation: checkpoint blockade etc.Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies.Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab.Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer.Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab.Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients.Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma.Cancer immunotherapy: A need for peripheral immunodynamic monitoring.Baseline laboratory parameters predicting clinical outcome in melanoma patients treated with ipilimumab: a single-centre analysis.Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy.Individually addressable and dynamic DNA gates for multiplexed cell sorting.Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment.Targeting immune checkpoints in melanoma: an update Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

P2860

Q26770780-FFE95A72-F460-435A-A779-E479837163F0 Q26796099-EF2138EC-CD9B-4672-B095-36A57CD06A26 Q26830509-A8F5B9CB-E7F3-45A8-8031-5E1ADC9E7F53 Q33688931-3B4A6668-5428-45CB-A30B-99EB127570D1 Q35235365-B2E88CAE-FECD-4C1D-867F-D129C7C4E408 Q35799695-A2A1E60C-E57B-43BA-99D4-C9DC27B4395B Q36020800-0E641E49-73FE-4823-B4BC-B91F9666B2E8 Q36711007-3BB71944-3C4E-4EEC-A05F-476AD8879825 Q36804897-5ADADA2D-C184-4EDD-9DAD-736F04C7389B Q36821143-2499EC5C-4F6E-4A0B-897A-6F002848EF0C Q37148418-9B99BBC8-390E-4597-8B13-23E343337AE5 Q38184391-5050B179-B472-4547-88C0-0981302D1062 Q38231154-81276C91-DCF8-4C7A-8845-3EE3662733B8 Q38297892-EF66DCB5-EB16-44CC-BBD8-BC2CC6C09B42 Q38306150-71F25184-3ED3-48BD-B903-312BB6E20329 Q38611895-0F2A6B13-1CFE-4B9C-84D6-ED940F8BF0DF Q38620081-2A0A4B22-7935-4593-9F6B-8250F1B42248 Q39187442-EA462378-1F57-4880-8B25-C854F5CF56CD Q39873712-2274E3E5-F0D5-4D6F-8CB0-F7482B26C4B5 Q40758666-7B3E9CD3-65DD-42CA-8939-61CC07366382 Q40964128-1F9F0E62-FA20-4662-B936-DE626FA2CBE6 Q42369277-328CBB31-0515-4594-B149-23E2B63D3D3A Q42369857-600F677E-7A70-4F2C-9AF3-40011CFBCFCA Q42968783-995C1D93-CC0B-4D0F-8878-1B3DD135293A Q43127268-BE6549BA-4CCC-4F79-A73E-47D4DC7FD191 Q44017442-8A0E0DBE-6F1A-47F8-B5E5-619F487B6C24 Q45765887-D44FEA36-7566-4417-8D58-974D43182A81 Q46865924-7C249814-D066-4393-A37F-5C9A409960B8 Q47561904-A7F343F9-C3AF-42A7-9C07-1517035A210C Q47812209-D41E5220-CF3B-41F8-AB9F-11B3344FC09B Q50191687-C72A240E-6524-483D-8091-0EAECF7A3BD0 Q50796572-9F443CC7-2792-4E94-AB88-1CACCFFB6297 Q52327546-40091BAB-F773-4B9C-B82C-F37A32E75441 Q55114350-4464ED9C-64DA-4947-9F27-561668C8E084 Q56895678-C689F2B1-610D-401B-A3F5-BE7528D01826 Q57781473-BBF70D04-6D4F-4766-A396-BB44C7D27AA3

P2860

Biomarkers on melanoma patient T cells associated with ipilimumab treatment.

http://www.wikidata.org/entity/Q36480617

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Biomarkers on melanoma patient T cells associated with ipilimumab treatment.

@ast

Biomarkers on melanoma patient T cells associated with ipilimumab treatment.

@en

type

label

Biomarkers on melanoma patient T cells associated with ipilimumab treatment.

@ast

Biomarkers on melanoma patient T cells associated with ipilimumab treatment.

@en

prefLabel

Biomarkers on melanoma patient T cells associated with ipilimumab treatment.

@ast

Biomarkers on melanoma patient T cells associated with ipilimumab treatment.

@en

P1433

Q36480617-7AC2659E-8B10-4C12-BE6B-092EA4293468

P1476

Q36480617-CB31BC1B-C1A3-4BDC-AA63-B920F0F3804E

P2093

Q36480617-10D622BA-7C87-4B17-876D-5F369647B2EB

Q36480617-29CA01AB-063E-4CCA-BFEA-12E0EDC809F0

Q36480617-3C1641FD-4D94-4624-A395-13A54297C9DF

Q36480617-90BE0D87-4D7B-4D91-A58A-B0F5A7FC1355

Q36480617-9A41B04C-F907-413E-B57A-E7FF26EA3732

Q36480617-9F81FF5A-603A-4F30-8F55-23EA08DE618D

Q36480617-BDB658DB-6E4A-45C4-A49B-93373BE6A404

Q36480617-CECF0926-A0A3-45C1-8E05-8D46DB359E30

Q36480617-E9782905-8A81-4D95-BFEF-911162535950

P2860

Q36480617-0070A33C-F919-434F-88E4-1607E69C2426

Q36480617-067FD0B6-D45F-45D5-876D-881CC789101B

Q36480617-0CC570BB-00B6-48B4-9BC6-61C4EDEEE3CD

Q36480617-170E4F95-5498-4C02-9A55-21A0989E2571

Q36480617-1ACB28AE-FA62-4E1C-B7A6-B87415A4A7B9

Q36480617-2405B637-723C-4A7C-94E0-9AD5CF1BAEFA

Q36480617-2E85A0CC-F477-455A-A1CC-0081E4800E31

Q36480617-330115DA-A5CB-44B8-9348-4399FE837C24

Q36480617-3557AA5F-0911-4851-83A2-18FB4C7623A5

Q36480617-38D4BF20-9407-4F64-8D10-F7C28501CE55

P2888

Q36480617-91EE811C-E535-45F9-8654-AE2124AF549D

P304

Q36480617-43964F6C-5DB6-4B77-8153-2FF03EA61EAD

P31

Q36480617-2927C85B-5823-4E20-A3C6-1610C02B36AF

P356

Q36480617-DD404C7E-8C8B-4FB3-A731-5D53F5BB4EAB

P478

Q36480617-54E58EE3-5A8F-422D-A656-A8DC65BDE2BC

P577

Q36480617-0761711B-391D-49F0-8FED-20A49CA794DB

P5875

Q36480617-C8BA0026-534F-475C-8367-FDCED6E8B9E9

P6179

Q36480617-65A2C9DE-8290-4279-8A22-76D98D4BE07D

P698

Q36480617-559EE1E0-CBFF-4383-BB89-31B3B601CEF6

P921

Q36480617-41D3F49B-7919-4DF5-BB22-450531B63FDF

Q36480617-51674FD5-4B9E-4F76-9F7B-79076A8CDEB0

Q36480617-DA8FC36F-DF78-48F4-9D5F-8AB774E3BC9D

P932

Q36480617-81A749C4-8B79-4DDA-834B-6F3CFFF3BBF5

P356

1479-5876-10-146

P1433

Journal of Translational Medicine

P1476

Biomarkers on melanoma patient T cells associated with ipilimumab treatment.

@en

P2093

Amod A Sarnaik

http://www.w3.org/2001/XMLSchema#string

Bin Yu

http://www.w3.org/2001/XMLSchema#string

Daohai Yu

http://www.w3.org/2001/XMLSchema#string

Dawn Morelli

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Weber

http://www.w3.org/2001/XMLSchema#string

Maclean Hall

http://www.w3.org/2001/XMLSchema#string

Wenshi Wang

http://www.w3.org/2001/XMLSchema#string

Xiuhua Zhao

http://www.w3.org/2001/XMLSchema#string

Yonghong Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma

The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Summaries of Affymetrix GeneChip probe level data

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

The Ki-67 protein: from the known and the unknown

ICOS co-stimulatory receptor is essential for T-cell activation and function

Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease

Enhancement of antitumor immunity by CTLA-4 blockade

P2888

1479-5876-10-146

P304

146

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1479-5876-10-146

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229079953

http://www.w3.org/2001/XMLSchema#string

P6179

1018588583

http://www.w3.org/2001/XMLSchema#string

P698

22788688

http://www.w3.org/2001/XMLSchema#string

P921

P932

3527361

http://www.w3.org/2001/XMLSchema#string